168 related articles for article (PubMed ID: 32239692)
41. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents.
Traynor MJ; Turner RB; Evans CR; Khengar RH; Jones SA; Brown MB
J Pharm Pharmacol; 2010 Jun; 62(6):730-7. PubMed ID: 20636860
[TBL] [Abstract][Full Text] [Related]
42. Emergence of nail lacquers as potential transungual delivery system in the management of onchomycosis.
Kataria P; Sharma G; Thakur K; Bansal V; Dogra S; Katare OP
Expert Opin Drug Deliv; 2016 Jul; 13(7):937-52. PubMed ID: 27054394
[TBL] [Abstract][Full Text] [Related]
43. A platform for predicting and enhancing model drug delivery across the human nail plate.
Vaka SR; Murthy SN; O'Haver JH; Repka MA
Drug Dev Ind Pharm; 2011 Jan; 37(1):72-9. PubMed ID: 20545509
[TBL] [Abstract][Full Text] [Related]
44. Topical anthralin therapy for refractory nail psoriasis.
Yamamoto T; Katayama I; Nishioka K
J Dermatol; 1998 Apr; 25(4):231-3. PubMed ID: 9609979
[TBL] [Abstract][Full Text] [Related]
45. Visualisation of penetration of topical antifungal drug substances through mycosis-infected nails by matrix-assisted laser desorption ionisation mass spectrometry imaging.
Endringer Pinto F; Bagger C; Kunze G; Joly-Tonetti N; Thénot JP; Osman-Ponchet H; Janfelt C
Mycoses; 2020 Aug; 63(8):869-875. PubMed ID: 32406142
[TBL] [Abstract][Full Text] [Related]
46. A pharmaceutics perspective on drug delivery to the nail: recent advances and challenges.
Delgado-Charro MB
Ther Deliv; 2015 Jul; 6(7):773-5. PubMed ID: 26228770
[No Abstract] [Full Text] [Related]
47. An investigation into keratinolytic enzymes to enhance ungual drug delivery.
Mohorcic M; Torkar A; Friedrich J; Kristl J; Murdan S
Int J Pharm; 2007 Mar; 332(1-2):196-201. PubMed ID: 17097244
[TBL] [Abstract][Full Text] [Related]
48. Treatment of severe nail psoriasis with acitretin: an impressive therapeutic result.
Ricceri F; Pescitelli L; Tripo L; Bassi A; Prignano F
Dermatol Ther; 2013; 26(1):77-8. PubMed ID: 23384024
[TBL] [Abstract][Full Text] [Related]
49. Dystrophic psoriatic fingernails treated with 1% 5-fluorouracil in a nail penetration-enhancing vehicle: a double-blind study.
de Jong EM; Menke HE; van Praag MC; van De Kerkhof PC
Dermatology; 1999; 199(4):313-8. PubMed ID: 10640840
[TBL] [Abstract][Full Text] [Related]
50. New Polyurethane Nail Lacquers for the Delivery of Terbinafine: Formulation and Antifungal Activity Evaluation.
Gregorí Valdes BS; Serro AP; Gordo PM; Silva A; Gonçalves L; Salgado A; Marto J; Baltazar D; Dos Santos RG; Bordado JM; Ribeiro HM
J Pharm Sci; 2017 Jun; 106(6):1570-1577. PubMed ID: 28263845
[TBL] [Abstract][Full Text] [Related]
51. [Diagnosis and management of nail psoriasis].
Sánchez-Regaña M; Umbert P
Actas Dermosifiliogr; 2008; 99(1):34-43. PubMed ID: 18206085
[TBL] [Abstract][Full Text] [Related]
52. Evaluation of the promoting effect of soluble cyclodextrins in drug nail penetration.
Gómez EC; Anguiano Igea S; Gómez Amoza JL; Otero Espinar FJ
Eur J Pharm Sci; 2018 May; 117():270-278. PubMed ID: 29501459
[TBL] [Abstract][Full Text] [Related]
53. Topical application of acidified nitrite to the nail renders it antifungal and causes nitrosation of cysteine groups in the nail plate.
Finnen MJ; Hennessy A; McLean S; Bisset Y; Mitchell R; Megson IL; Weller R
Br J Dermatol; 2007 Sep; 157(3):494-500. PubMed ID: 17627796
[TBL] [Abstract][Full Text] [Related]
54. Investigation of different formulations for drug delivery through the nail plate.
Vejnovic I; Simmler L; Betz G
Int J Pharm; 2010 Feb; 386(1-2):185-94. PubMed ID: 19941943
[TBL] [Abstract][Full Text] [Related]
55. Alteration of the diffusional barrier property of the nail leads to greater terbinafine drug loading and permeation.
Nair AB; Sammeta SM; Kim HD; Chakraborty B; Friden PM; Murthy SN
Int J Pharm; 2009 Jun; 375(1-2):22-7. PubMed ID: 19481686
[TBL] [Abstract][Full Text] [Related]
56. Effectiveness of systemic treatment agents on psoriatic nails: a comparative study.
Demirsoy EO; Kıran R; Salman S; Cağlayan C; Aktürk AS; Bayramgurler D; Bilen N
J Drugs Dermatol; 2013 Sep; 12(9):1039-43. PubMed ID: 24002153
[TBL] [Abstract][Full Text] [Related]
57. Nail psoriasis: combined therapy with systemic cyclosporin and topical calcipotriol.
Feliciani C; Zampetti A; Forleo P; Cerritelli L; Amerio P; Proietto G; Tulli A; Amerio P
J Cutan Med Surg; 2004; 8(2):122-5. PubMed ID: 15129317
[TBL] [Abstract][Full Text] [Related]
58. UV-curable gel formulations: Potential drug carriers for the topical treatment of nail diseases.
Kerai LV; Hilton S; Murdan S
Int J Pharm; 2015 Aug; 492(1-2):177-90. PubMed ID: 26187167
[TBL] [Abstract][Full Text] [Related]
59. Treatment of psoriatic nails with topical cyclosporin: a prospective, randomized placebo-controlled study.
Cannavò SP; Guarneri F; Vaccaro M; Borgia F; Guarneri B
Dermatology; 2003; 206(2):153-6. PubMed ID: 12592084
[TBL] [Abstract][Full Text] [Related]
60. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: A dermatologist and nail expert group consensus.
Rigopoulos D; Baran R; Chiheb S; Daniel CR; Di Chiacchio N; Gregoriou S; Grover C; Haneke E; Iorizzo M; Pasch M; Piraccini BM; Rich P; Richert B; Rompoti N; Rubin AI; Singal A; Starace M; Tosti A; Triantafyllopoulou I; Zaiac M
J Am Acad Dermatol; 2019 Jul; 81(1):228-240. PubMed ID: 30731172
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
